Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH)
Publication
, Conference
Ruppe, MD; Zhang, X; Imel, EA; Weber, TJ; Klausner, M; Ito, T; Vergeire, M; Humphrey, J; Glorieux, FH; Portale, AA; Insogna, K; Peacock, M ...
Published in: Endocrine Reviews
June 1, 2014
Duke Scholars
Published In
Endocrine Reviews
EISSN
1945-7189
ISSN
0163-769X
Publication Date
June 1, 2014
Volume
35
Issue
3
Publisher
ENDOCRINE SOC
Related Subject Headings
- Endocrinology & Metabolism
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 0601 Biochemistry and Cell Biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ruppe, M. D., Zhang, X., Imel, E. A., Weber, T. J., Klausner, M., Ito, T., … Carpenter, T. O. (2014). Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH). In Endocrine Reviews (Vol. 35). ENDOCRINE SOC.
Ruppe, Mary Denise, Xiaoping Zhang, Erik Allen Imel, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, et al. “Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH).” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.
Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner M, Ito T, et al. Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH). In: Endocrine Reviews. ENDOCRINE SOC; 2014.
Ruppe, Mary Denise, et al. “Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH).” Endocrine Reviews, vol. 35, no. 3, ENDOCRINE SOC, 2014.
Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner M, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH). Endocrine Reviews. ENDOCRINE SOC; 2014.
Published In
Endocrine Reviews
EISSN
1945-7189
ISSN
0163-769X
Publication Date
June 1, 2014
Volume
35
Issue
3
Publisher
ENDOCRINE SOC
Related Subject Headings
- Endocrinology & Metabolism
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 0601 Biochemistry and Cell Biology